Renal Mitochondrial Cytopathies
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
BOLA3 Deficiency Controls Endothelial Metabolism and Glycine Homeostasis in Pulmonary Hypertension
BOLA (BolA Family Member 3) Deficiency Controls Endothelial Metabolism and Glycine Homeostasis in Pulmonary Hypertension The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation Yu, Qiujun et al. “BOLA (BolA Family Member 3) Deficiency Controls Endothelial Metabolism and Glycine Homeostasis in Pulmonary Hypertension.” Circulation 139 (2019): 2238-2255 © 2019 The Author(s) As Published https://dx.doi.org/10.1161/CIRCULATIONAHA.118.035889 Publisher Ovid Technologies (Wolters Kluwer Health) Version Author's final manuscript Citable link https://hdl.handle.net/1721.1/125622 Terms of Use Creative Commons Attribution-Noncommercial-Share Alike Detailed Terms http://creativecommons.org/licenses/by-nc-sa/4.0/ HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Circulation Manuscript Author . Author manuscript; Manuscript Author available in PMC 2020 May 07. Published in final edited form as: Circulation. 2019 May 07; 139(19): 2238–2255. doi:10.1161/CIRCULATIONAHA.118.035889. BOLA3 deficiency controls endothelial metabolism and glycine homeostasis in pulmonary hypertension Qiujun Yu, MD, PhD1, Yi-Yin Tai, MS1, Ying Tang, MS1, Jingsi Zhao, MS1, Vinny Negi, PhD1, Miranda K. Culley, BA1, Jyotsna Pilli, PhD1, Wei Sun, MD1, Karin Brugger, MD2, Johannes Mayr, MD2, Rajeev Saggar, MD3, Rajan Saggar, MD4, W. Dean Wallace, MD4, David J. Ross, MD4, Aaron B. Waxman, MD, PhD5, Stacy G. Wendell, PhD6,7, Steven J. Mullett, BS7, John Sembrat, BS1, Mauricio Rojas, MD1, Omar F. Khan, PhD8, James E. Dahlman, PhD9, Masataka Sugahara, MD1, Nobuyuki Kagiyama, MD1, Taijyu Satoh, MD1, Manling Zhang, MD, MS1, Ning Feng, MD, PhD1, John Gorcsan III, MD10, Sara O. -
Citric Acid Cycle
CHEM464 / Medh, J.D. The Citric Acid Cycle Citric Acid Cycle: Central Role in Catabolism • Stage II of catabolism involves the conversion of carbohydrates, fats and aminoacids into acetylCoA • In aerobic organisms, citric acid cycle makes up the final stage of catabolism when acetyl CoA is completely oxidized to CO2. • Also called Krebs cycle or tricarboxylic acid (TCA) cycle. • It is a central integrative pathway that harvests chemical energy from biological fuel in the form of electrons in NADH and FADH2 (oxidation is loss of electrons). • NADH and FADH2 transfer electrons via the electron transport chain to final electron acceptor, O2, to form H2O. Entry of Pyruvate into the TCA cycle • Pyruvate is formed in the cytosol as a product of glycolysis • For entry into the TCA cycle, it has to be converted to Acetyl CoA. • Oxidation of pyruvate to acetyl CoA is catalyzed by the pyruvate dehydrogenase complex in the mitochondria • Mitochondria consist of inner and outer membranes and the matrix • Enzymes of the PDH complex and the TCA cycle (except succinate dehydrogenase) are in the matrix • Pyruvate translocase is an antiporter present in the inner mitochondrial membrane that allows entry of a molecule of pyruvate in exchange for a hydroxide ion. 1 CHEM464 / Medh, J.D. The Citric Acid Cycle The Pyruvate Dehydrogenase (PDH) complex • The PDH complex consists of 3 enzymes. They are: pyruvate dehydrogenase (E1), Dihydrolipoyl transacetylase (E2) and dihydrolipoyl dehydrogenase (E3). • It has 5 cofactors: CoASH, NAD+, lipoamide, TPP and FAD. CoASH and NAD+ participate stoichiometrically in the reaction, the other 3 cofactors have catalytic functions. -
WO 2016/115632 Al 28 July 2016 (28.07.2016) W P O P C T
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/115632 Al 28 July 2016 (28.07.2016) W P O P C T (51) International Patent Classification: (72) Inventors: TARNOPOLSKY, Mark; 309-397 King C12N 5/ 0 (2006.01) C12N 15/53 (2006.01) Street West, Dundas, Ontario L9H 1W9 (CA). SAFDAR, A61K 35/12 (2015.01) C12N 15/54 (2006.01) Adeel; c/o McMaster University, 1200 Main Street West, A61K 9/51 (2006.01) C12N 15/55 (2006.01) Hamilton, Ontario L8N 3Z5 (CA). C12N 15/11 (2006.01) C12N 15/85 (2006.01) (74) Agent: TANDAN, Susan; Gowling WLG (Canada) LLP, C12N 15/12 (2006.01) C12N 5/071 (2010.01) One Main Street West, Hamilton, Ontario L8P 4Z5 (CA). (21) International Application Number: (81) Designated States indicated, PCT/CA20 16/050046 (unless otherwise for every kind of national protection available): AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, 2 1 January 2016 (21 .01 .2016) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (25) Filing Language: English HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (26) Publication Language: English KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (30) Priority Data: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 62/105,967 2 1 January 2015 (21.01.2015) US SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 62/1 12,940 6 February 2015 (06.02.2015) US TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. -
Eႇects of Alternative Oxidase on Drosophila Under Environmental
6,1$6$$5, (ႇHFWVRI$OWHUQDWLYH 2[LGDVHRQDrosophila XQGHU(QYLURQPHQWDO6WUHVV 7DPSHUH8QLYHUVLW\'LVVHUWDWLRQV 7DPSHUH8QLYHUVLW\'LVVHUWDWLRQV 6,1$6$$5, (IIHFWVRI$OWHUQDWLYH 2[LGDVHRQDrosophila XQGHU(QYLURQPHQWDO6WUHVV $&$'(0,&',66(57$7,21 7REHSUHVHQWHGZLWKWKHSHUPLVVLRQRI WKH)DFXOW\RI0HGLFLQHDQG+HDOWK7HFKQRORJ\ RI7DPSHUH8QLYHUVLW\ IRUSXEOLFGLVFXVVLRQLQWKHDXGLWRULXP) RIWKH$UYREXLOGLQJ$UYR<OS|QNDWX7DPSHUH RQ2FWREHUDWR¶FORFN $&$'(0,&',66(57$7,21 7DPSHUH8QLYHUVLW\)DFXOW\RI0HGLFLQHDQG+HDOWK7HFKQRORJ\ )LQODQG Responsible 3URIHVVRU+RZDUG7-DFREV supervisor 7DPSHUH8QLYHUVLW\ and Custos )LQODQG Pre-examiners 3URIHVVRU:LOOLDP-%DOODUG 'RFHQW(LMD3LULQHQ 8QLYHUVLW\RI1HZ6RXWK:DOHV 8QLYHUVLW\RI+HOVLQNL $XVWUDOLD )LQODQG Opponent $VVRFLDWH3URIHVVRU9LOOH+LHWDNDQJDV 8QLYHUVLW\RI+HOVLQNL )LQODQG 7KHRULJLQDOLW\RIWKLVWKHVLVKDVEHHQFKHFNHGXVLQJWKH7XUQLWLQ2ULJLQDOLW\&KHFN VHUYLFH &RS\ULJKWDXWKRU &RYHUGHVLJQ5RLKX,QF ,6%1 SULQW ,6%1 SGI ,661 SULQW ,661 SGI KWWSXUQIL851,6%1 3XQD0XVWD2\±<OLRSLVWRSDLQR 7DPSHUH To Pulla iii iv ABSTRACT The mitochondrion is a unique organelle with a central role in energy production and metabolic homeostasis while regulating the life and death of the entire cell. In mitochondrial dysfunction, deficiencies or abnormalities of the mitochondrial oxidative phosphorylation (OXPHOS) system impair cellular energy production. Due to its ability to bypass Complex III and IV of the OXPHOS system and divert electrons from ubiquinol to oxygen, the mitochondrial alternative oxidase (AOX) has drawn attention as a potential -
Mitochondrial Genetics
Mitochondrial genetics Patrick Francis Chinnery and Gavin Hudson* Institute of Genetic Medicine, International Centre for Life, Newcastle University, Central Parkway, Newcastle upon Tyne NE1 3BZ, UK Introduction: In the last 10 years the field of mitochondrial genetics has widened, shifting the focus from rare sporadic, metabolic disease to the effects of mitochondrial DNA (mtDNA) variation in a growing spectrum of human disease. The aim of this review is to guide the reader through some key concepts regarding mitochondria before introducing both classic and emerging mitochondrial disorders. Sources of data: In this article, a review of the current mitochondrial genetics literature was conducted using PubMed (http://www.ncbi.nlm.nih.gov/pubmed/). In addition, this review makes use of a growing number of publically available databases including MITOMAP, a human mitochondrial genome database (www.mitomap.org), the Human DNA polymerase Gamma Mutation Database (http://tools.niehs.nih.gov/polg/) and PhyloTree.org (www.phylotree.org), a repository of global mtDNA variation. Areas of agreement: The disruption in cellular energy, resulting from defects in mtDNA or defects in the nuclear-encoded genes responsible for mitochondrial maintenance, manifests in a growing number of human diseases. Areas of controversy: The exact mechanisms which govern the inheritance of mtDNA are hotly debated. Growing points: Although still in the early stages, the development of in vitro genetic manipulation could see an end to the inheritance of the most severe mtDNA disease. Keywords: mitochondria/genetics/mitochondrial DNA/mitochondrial disease/ mtDNA Accepted: April 16, 2013 Mitochondria *Correspondence address. The mitochondrion is a highly specialized organelle, present in almost all Institute of Genetic Medicine, International eukaryotic cells and principally charged with the production of cellular Centre for Life, Newcastle energy through oxidative phosphorylation (OXPHOS). -
Biallelic Variants in HPDL Cause Pure and Complicated Hereditary Spastic Paraplegia
doi:10.1093/brain/awab041 BRAIN 2021: Page 1 of 15 | 1 Downloaded from https://academic.oup.com/brain/advance-article/doi/10.1093/brain/awab041/6273093 by Motol Teaching Hospital user on 02 June 2021 Biallelic variants in HPDL cause pure and complicated hereditary spastic paraplegia Manuela Wiessner,1,† Reza Maroofian,2,† Meng-Yuan Ni,3,† Andrea Pedroni,4,† Juliane S. Mu¨ller,5,6 Rolf Stucka,1 Christian Beetz,7 Stephanie Efthymiou,2 Filippo M. Santorelli,8 Ahmed A. Alfares,9 Changlian Zhu,10,11,12 Anna Uhrova Meszarosova,13 Elham Alehabib,14 Somayeh Bakhtiari,15 Andreas R. Janecke,16 Maria Gabriela Otero,17 Jin Yun Helen Chen,18 James T. Peterson,19 Tim M. Strom,20 Peter De Jonghe,21,22,23 Tine Deconinck,24 Willem De Ridder,21,22,23 Jonathan De Winter, 21,22,23 Rossella Pasquariello,8 Ivana Ricca,8 Majid Alfadhel,25 Bart P.van de Warrenburg,26,27 Ruben Portier,28 Carsten Bergmann,29 Saghar Ghasemi Firouzabadi,30 Sheng Chih Jin,31 Kaya Bilguvar,32,33 Sherifa Hamed,34 Mohammed Abdelhameed,34 Nourelhoda A. Haridy,2,34 Shazia Maqbool,35 Fatima Rahman,35 Najwa Anwar,35 Jenny Carmichael,36 Alistair Pagnamenta,37 Nick W. Wood,2,38 Frederic Tran Mau-Them,39 Tobias Haack,40 Genomics England Research Consortium, PREPARE network, Maja Di Rocco,41 Isabella Ceccherini,41 Michele Iacomino,41 Federico Zara,41,42 Vincenzo Salpietro,41,42 Marcello Scala,2 Marta Rusmini,41 Yiran Xu,10 Yinghong Wang,43 Yasuhiro Suzuki,44 Kishin Koh,45 Haitian Nan,45 Hiroyuki Ishiura,46 Shoji Tsuji,47 Lae¨titia Lambert,48 Emmanuelle Schmitt,49 Elodie Lacaze,50 Hanna Ku¨pper,51 David Dredge,18 Cara Skraban,52,53 Amy Goldstein,19,53 Mary J. -
The Citric Acid Cycle
Chapter 16 The Citric Acid Cycle: CAC Kreb’s Cycle Tricarboxylic Acid Cycle: TCA The Citric Acid Cycle Key topics: To Know – Also called Tricarboxylic Acid Cycle (TCA) or Krebs Cycle. Three names for the same thing. – Cellular respiration and intermediates for biosynthesis. – Conversion of pyruvate to activated acetate – Reactions of the citric acid cycle – Anaplerotic reactions to regenerate the acceptor – Regulation of the citric acid cycle – Conversion of acetate to carbohydrate precursors in the glyoxylate cycle Discovered CAC in Pigeon Flight Muscle Cellular Respiration • Process in which cells consume O2 and produce CO2 • Provides more energy (ATP) from glucose than Glycolysis • Also captures energy stored in lipids and amino acids • Evolutionary origin: developed about 2.5 billion years ago • Used by animals, plants, and many microorganisms • Occurs in three major stages: - acetyl CoA production (This chapter) - acetyl CoA oxidation (This chapter) - electron transfer and oxidative phosphorylation (Chapter 19) Overall Picture Overall Picture Acetyl-CoA production The area blocked off all occurs in the takes place in the mitochondria. Mitochondrion. So, first pyruvate has to get Acetyl-CoA enters the transported from the CAC. cytoplasm into the mitochondrion. In this Figure, only Glycolysis is in the Cytoplasm. Pyr DH is a Complex Enzyme Pyruvate Dehydrogenase Model TEM Lipoic Acid is linked to a Lys (K) Remember HSCoA ? from Chapter 1 It is down here One Unit of Pyr DH EOC Problem 6: Tests your knowledge of PyrDH. EOC Problem 7: Thiamin deficiency and blood pyruvate. Pyr DH is a Cool Enzyme EOC Problem 5: NAD+ in oxidation and reduction reactions (a through f should be easy). -
Genetic Regulation of the Host Response to Cardiac Surgery and Cardiopulmonary Bypass
Genetic regulation of the host response to cardiac surgery and cardiopulmonary bypass E.M.SVOREN MBBS, FRCA, EDIC. 1 | P a g e Statement of originality I, Eduardo M Svoren, confirm that the research included within this thesis is my own work or that where it has been carried out in collaboration with, or supported by others, that this is duly acknowledged below and my contribution indicated. Previously published material is also acknowledged below. I attest that I have exercised reasonable care to ensure that the work is original, and does not to the best of my knowledge break any UK law, infringe any third party’s copyright or other Intellectual Property Right, or contain any confidential material. I accept that the College has the right to use plagiarism detection software to check the electronic version of the thesis. I confirm that this thesis has not been previously submitted for the award of a degree by this or any other university. The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without the prior written consent of the author. Signature: Date: Contributors I am very grateful to the research nurses, Ms Alice Purdy and Eli McAlees, for their collaboration in patient recruitment and blood sampling. Both genome-wide expression array and genotyping arrays (Illumina R™) were processed at the Wellcome Trust Sanger Institute, Cambridge. Peter Hamburg and Emma Davenport collaborated in the eQTL analysis. 2 | P a g e Acknowledgments To Professor Charles Hinds whose support and encouragement made possible what I had considered for many years a dream. -
Lecture 9: Citric Acid Cycle/Fatty Acid Catabolism
Metabolism Lecture 9 — CITRIC ACID CYCLE/FATTY ACID CATABOLISM — Restricted for students enrolled in MCB102, UC Berkeley, Spring 2008 ONLY Bryan Krantz: University of California, Berkeley MCB 102, Spring 2008, Metabolism Lecture 9 Reading: Ch. 16 & 17 of Principles of Biochemistry, “The Citric Acid Cycle” & “Fatty Acid Catabolism.” Symmetric Citrate. The left and right half are the same, having mirror image acetyl groups (-CH2COOH). Radio-label Experiment. The Krebs Cycle was tested by 14C radio- labeling experiments. In 1941, 14C-Acetyl-CoA was used with normal oxaloacetate, labeling only the right side of drawing. But none of the label was released as CO2. Always the left carboxyl group is instead released as CO2, i.e., that from oxaloacetate. This was interpreted as proof that citrate is not in the 14 cycle at all the labels would have been scrambled, and half of the CO2 would have been C. Prochiral Citrate. In a two-minute thought experiment, Alexander Ogston in 1948 (Nature, 162: 963) argued that citrate has the potential to be treated as chiral. In chemistry, prochiral molecules can be converted from achiral to chiral in a single step. The trick is an asymmetric enzyme surface (i.e. aconitase) can act on citrate as through it were chiral. As a consequence the left and right acetyl groups are not treated equivalently. “On the contrary, it is possible that an asymmetric enzyme which attacks a symmetrical compound can distinguish between its identical groups.” Metabolism Lecture 9 — CITRIC ACID CYCLE/FATTY ACID CATABOLISM — Restricted for students enrolled in MCB102, UC Berkeley, Spring 2008 ONLY [STEP 4] α-Keto Glutarate Dehydrogenase. -
Novel Methionyl-Trna Synthetase Gene Variants/ Phenotypes in Interstitial Lung and Liver Disease: a Case Report and Review of Literature
Submit a Manuscript: http://www.f6publishing.com World J Gastroenterol 2018 September 28; 24(36): 4208-4216 DOI: 10.3748/wjg.v24.i36.4208 ISSN 1007-9327 (print) ISSN 2219-2840 (online) CASE REPORT Novel methionyl-tRNA synthetase gene variants/ phenotypes in interstitial lung and liver disease: A case report and review of literature Kuerbanjiang Abuduxikuer, Jia-Yan Feng, Yi Lu, Xin-Bao Xie, Lian Chen, Jian-She Wang Kuerbanjiang Abuduxikuer, Yi Lu, Xin-Bao Xie, Jian-She licenses/by-nc/4.0/ Wang, Department of Hepatology, Children’s Hospital of Fudan University, Shanghai 201102, China Manuscript source: Unsolicited manuscript Jia-Yan Feng, Lian Chen, Department of Pathology, Children’s Correspondence to: Jian-She Wang, MD, PhD, Professor, Hospital of Fudan University, Shanghai 201102, China Department of Hepatology, Children’s Hospital of Fudan University, 399 Wanyuan Road, Shanghai 201102, Jian-She Wang, Department of Pediatrics, Jinshan Hospital of China. [email protected] Fudan University, Shanghai 201508, China Telephone: +86-21-64931171 Fax: +86-21-64931171 ORCID number: Kuerbanjiang Abuduxikuer (0000-0003 -0298-3269); Jia-Yan Feng (0000-0002-6651-4675); Yi Lu Received: June 21, 2018 (0000-0002-3311-4501); Xin-Bao Xie (0000-0002-3692 Peer-review started: June 22, 2018 -7356); Lian Chen (0000-0002-0545-2108); Jian-She Wang First decision: July 31, 2018 (0000-0003-0823-586X). Revised: August 2, 2018 Accepted: August 24, 2018 Author contributions: Wang JS designed the report and Article in press: August 24, 2018 approved the final submission; Abuduxikuer K collected data, Published online: September 28, 2018 analyzed relevant information, and wrote the manuscript; Wang JS, Lu Y, Xie XB, and Abuduxikuer K clinically managed the patient; Feng JY, Chen L analyzed liver biopsy samples. -
Identification of Genetic Modifiers in Hereditary Spastic Paraplegias Due to SPAST/SPG4 Mutations Livia Parodi
Identification of genetic modifiers in Hereditary Spastic Paraplegias due to SPAST/SPG4 mutations Livia Parodi To cite this version: Livia Parodi. Identification of genetic modifiers in Hereditary Spastic Paraplegias due to SPAST/SPG4 mutations. Human health and pathology. Sorbonne Université, 2019. English. NNT : 2019SORUS317. tel-03141229 HAL Id: tel-03141229 https://tel.archives-ouvertes.fr/tel-03141229 Submitted on 15 Feb 2021 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Sorbonne Université Institut du Cerveau et de la Moelle Épinière École Doctorale Cerveau-Cognition-Comportement Thèse de doctorat en Neurosciences Identification of genetic modifiers in Hereditary Spastic Paraplegias due to SPAST/SPG4 mutations Soutenue le 9 octobre 2019 par Livia Parodi Membres du jury : Pr Bruno Stankoff Président Pr Lesley Jones Rapporteur Dr Susanne de Bot Rapporteur Pr Christel Depienne Examinateur Pr Cyril Goizet Examinateur Pr Alexandra Durr Directeur de thèse Table of contents Abbreviations _________________________________________________________ -
Mitochondria Targeting As an Effective Strategy for Cancer Therapy
International Journal of Molecular Sciences Review Mitochondria Targeting as an Effective Strategy for Cancer Therapy Poorva Ghosh , Chantal Vidal, Sanchareeka Dey and Li Zhang * Department of Biological Sciences, the University of Texas at Dallas, Richardson, TX 75080, USA; [email protected] (P.G.); [email protected] (C.V.); [email protected] (S.D.) * Correspondence: [email protected]; Tel.: +972-883-5757 Received: 25 February 2020; Accepted: 6 May 2020; Published: 9 May 2020 Abstract: Mitochondria are well known for their role in ATP production and biosynthesis of macromolecules. Importantly, increasing experimental evidence points to the roles of mitochondrial bioenergetics, dynamics, and signaling in tumorigenesis. Recent studies have shown that many types of cancer cells, including metastatic tumor cells, therapy-resistant tumor cells, and cancer stem cells, are reliant on mitochondrial respiration, and upregulate oxidative phosphorylation (OXPHOS) activity to fuel tumorigenesis. Mitochondrial metabolism is crucial for tumor proliferation, tumor survival, and metastasis. Mitochondrial OXPHOS dependency of cancer has been shown to underlie the development of resistance to chemotherapy and radiotherapy. Furthermore, recent studies have demonstrated that elevated heme synthesis and uptake leads to intensified mitochondrial respiration and ATP generation, thereby promoting tumorigenic functions in non-small cell lung cancer (NSCLC) cells. Also, lowering heme uptake/synthesis inhibits mitochondrial OXPHOS and effectively reduces oxygen consumption, thereby inhibiting cancer cell proliferation, migration, and tumor growth in NSCLC. Besides metabolic changes, mitochondrial dynamics such as fission and fusion are also altered in cancer cells. These alterations render mitochondria a vulnerable target for cancer therapy. This review summarizes recent advances in the understanding of mitochondrial alterations in cancer cells that contribute to tumorigenesis and the development of drug resistance.